47 results on '"Ryckewaert, Thomas"'
Search Results
2. Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study
3. La « Limitation et/ou arrêt des thérapeutiques » (LAT) en oncologie face à une situation aigüe : historique et aspects réglementaires en France
4. Exceptional Response to Dual Colony-Stimulating Factor 1 Receptor/PD-L1 Targeting After Primary Resistance to PD-1 Inhibition in a Patient With a Metastatic Uveal Melanoma
5. Traitements systémiques des fibromatoses agressives chez l’adulte et l’enfant : niveau de preuve et questions en suspens
6. PEC‐PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent
7. Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis
8. Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma
9. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group
10. Incidence et facteurs de risque de l’encéphalopathie à l’ifosfamide chez les patients suivis pour un sarcome
11. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial
12. Emerging Role of Multikinase Inhibitors in Desmoid Tumor Management
13. Corrigendum to ‘Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study’ [Eur J Cancer 171 (2022) 183–192]
14. Selection of ultimately ill cancer patients able to fulfill a questionnaire: Identification of inherent biases
15. Molecular targeted therapies in advanced or metastatic chordoma patients: Facts and hypotheses
16. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial
17. Comparison of Response Evaluation Criteria in Solid Tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: A retrospective analysis
18. What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials
19. Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
20. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial
21. Management of “unfavourable” carcinoma of unknown primary site: Synthesis of recent literature
22. Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
23. PEC-PRO: A new prognostic score from a series of 93 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent.
24. REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
25. Prognosis value of S45F mutation of CTNNB1 in desmoid-type fibromatosis (DF): Prospective analysis of 500 consecutive patients (pts) from ALTITUDES trial.
26. Rechallenge of nivolumab in metastatic renal cell carcinoma, an ambispective multicenter study (RENIVO).
27. Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials
28. Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals
29. Docetaxel (DOC) versus new androgen receptor-targeted agent (ART) in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) having received abiraterone (ABI) or enzalutamide (ENZA) as first-line (L1).
30. Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies
31. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib (REG) in patients (pts) with nonadipocytic soft tissue sarcoma (STS) previously treated with pazopanib (PAZ).
32. Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma
33. Additional file 3: of Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
34. Additional file 1: of Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
35. Additional file 4: of Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
36. Additional file 2: of Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
37. Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study.
38. Cancer de la prostate et docétaxel : plus tôt mais pas trop tôt
39. A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome
40. Prognosis of desmoid tumors (DT): A prospective nationwide survey of 771 patients (pts).
41. Paclitaxel once weekly (wP) combined with fixed dose of oral metronomic cyclophosphamide (OMC): A dose-escalating phase I trial.
42. Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas and GIST: A French Sarcoma Group phase II trial.
43. Is symptom worsening (SW) associated with RECIST response in patients (pts) with desmoid tumors (DT)?
44. Ewing sarcoma Family of Tumors in Older Patients (EFyTOP): Management and outcome of Ewing sarcoma family of tumors (EFTs) in patients older than 50 years.
45. Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial.
46. Risk factors for ifosfamide-related encephalopathy (IRE) in sarcoma (S) patients (pts).
47. Clinical experience with sunitinib (SU) in patients over age 65 with metastatic gastrointestinal stromal tumors (GIST): A retrospective study from the French Sarcoma Group (FSG)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.